Arris to acquire Khepri in $20-$22 mil. deal; hopes to lower burn rate 25%.
Executive Summary
ARRIS TO ACQUIRE KHEPRI FOR $20-$22 MIL., Arris Corp. announced Nov. 8 after signing a definitive agreement with Khepri Pharmaceuticals. The signing culminates talks initiated by Arris in the summer of 1994. Arris will issue 1.5 mil. shares of stock to Khepri shareholders in December, when the acquisition is expected to have its first-stage closing. At that time, the issued shares will be subject to contractual lock-up: approximately 1 mil. shares may not be sold to the public until Jan. 1, 1997. In the second stage of the closing, an additional 525,000 shares or their cash equivalent will be issued on Dec. 30, 1996.
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth